Morphotek And Sandy Rollman Ovarian Cancer Foundation Launch Educational Resource On Clinical Trials
EXTON, Pa., March 22, 2017 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., and the Sandy Rollman Ovarian Cancer Foundation (SROCF) announced today the launch of a resource to educate ovarian cancer patients and caregivers on clinical trials. Morphotek and SROCF collaborated on "Clinical Trials: A Start" after conducting a patient and caregiver roundtable on general barriers to clinical trial participation. It was evident during the roundtable that more needed to be done to demystify the complex topic of clinical trials and help patients and caregivers better understand this potential option. "Clinical Trials: A Start" is intended to address many of the questions and concerns raised by the roundtable participants. While it is not possible to address every question or possible clinical trial design in an educational brochure, we hope that this resource serves as a meaningful start for patients and caregivers.
Morphotek and SROCF are grateful to the women who participated in the roundtable and who helped to develop this educational resource. "Clinical Trials: A Start" is available for free download on SROCF's and Morphotek's websites.
"In light of our hhc Mission, we welcomed this opportunity to collaborate with the Sandy Rollman Ovarian Cancer Foundation to educate patients and caregivers on the often complex subject of clinical trials," said Nicholas Nicolaides, President and CEO of Morphotek. "We hope that 'Clinical Trials: A Start' proves to be an easy-to-understand resource that helps patients to have a more meaningful discussion with their healthcare provider on clinical trials."
"We're hopeful that this brochure might serve as a starting point for women fighting ovarian cancer to learn about potentially lifesaving clinical trials," said Robin Cohen, Co-Founder and CEO of the Sandy Rollman Ovarian Cancer Foundation. "Many women are unaware of or confused by the options available to them, and we hope to change that."
About the Sandy Rollman Ovarian Cancer Foundation
The Sandy Rollman Ovarian Cancer Foundation, Inc. is a non-profit, 501c3 organization created as a tribute to the life, character, and immense strength of Sandy Rollman. Sandy passed away from advanced ovarian cancer in May 2000. Prior to diagnosis, Sandy experienced many textbook symptoms. Her symptoms were whispering only no one was listening. The tragic result was that Sandy never had a chance against ovarian cancer. Her sister Adriana Way and her nurse Robin Cohen decided to keep Sandy's memory alive while trying to prevent other women from having to endure the same pain as she did. It is in Sandy's memory and the memory of all women who have succumbed to this insidious disease, that we have dedicated our efforts to help conquer ovarian cancer. Sandy Rollman was a fighter in the truest sense of the word. It would have been a mistake for us to just give up. Our mission is to fight for those who are fighting, speak for those who have fallen silent and provide for those who are working towards the end of ovarian cancer. For more information, please visit www.sandyovarian.org and follow us on Facebook and Twitter.
About Morphotek
Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.
About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
| Morphotek Contacts: |
|
| Investor Inquiries: |
Media Inquiries: |
| Rod Dausch |
Diana Martens |
| 610-423-6111 |
610-423-6085 |
| Sandy Rollman Ovarian Cancer Foundation Contact: |
|
| Media Inquiries: |
|
| Robin Cohen |
|
| 610-446-2272 |
|
SOURCE Morphotek, Inc.
Share this article